{"schema_version":"secwatch.filing_event.v1","accession":"0001645113-23-000036","form_type":"8-K","ticker":"NVCR","cik":"0001645113","company_name":"NovoCure Ltd","filed_at":"2023-04-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.816474+00:00","generated_at":"2026-06-16T13:02:01.156978+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Novocure LUNAR phase 3 NSCLC trial met primary endpoint; results at ASCO 2023","bullets":["LUNAR trial showed statistically significant improvement in overall survival with TTFields plus standard therapies in metastatic NSCLC.","Full results to be presented as a late-breaking abstract at ASCO 2023 on June 6, 2023, at 11:09 a.m. CDT.","Novocure will host an investor event on June 6 at 2 p.m. CDT to discuss the data.","First phase 3 trial evaluating TTFields outside the brain and with immunotherapy.","Ten abstracts on TTFields therapy, including LUNAR, will be presented at ASCO 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001645113-23-000036","json":"https://secwatch.observer/filing/0001645113-23-000036.json","markdown":"https://secwatch.observer/filing/0001645113-23-000036.md","text":"https://secwatch.observer/filing/0001645113-23-000036.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000036/0001645113-23-000036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000036/nvcr-20230426.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T13:02:01.156978+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}